Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms

Therapeutic Apheresis and Dialysis

Volumn 18, Issue SUPPL2, 2014, Pages 19-23

  Ito, Kae ^a   Takeshima, Akiko ^b   Shishido, Kanji ^a   Wakasa, Mikio ^a   Kumata, Chiaki ^a   Matsuzaka, Kantaro ^a   Nakajima, Yutaka ^a   Ogata, Hiroaki ^b  

^a Sekishin kai Kawasaki Clinic   (Japan)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

Adverse event; Bixalomer; Gastrointestinal symptom; Hemodialysis; Hyperphosphatemia

Indexed keywords

BICARBONATE; BIXALOMER; CALCIUM; CHLORIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; PICOSULFATE SODIUM; SENNA EXTRACT; SENNOSIDE; SERUM ALBUMIN; SEVELAMER; SORBITOL; TRIACYLGLYCEROL; CHELATING AGENT; LIPID; PHOSPHORUS; POLYAMINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL SYMPTOM RATING SCALE; HARD FECES; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; INDIGESTION; JAPANESE (PEOPLE); LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTPATIENT CARE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; JAPAN; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY;

ABDOMINAL PAIN; BICARBONATES; CALCIUM; CHELATING AGENTS; COHORT STUDIES; CONSTIPATION; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; HUMANS; HYPERPHOSPHATEMIA; JAPAN; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHORUS; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84903471229     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12229     Document Type: Article

References (22)

1. Ogata H, Koiwa F, Kinugasa E, Akizawa T. CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol 2007;11:261-268.
2. Ogata H, Koiwa F, Ito H, Kinugasa E. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients. Ther Apher Dial 2006;10:355-363.
3. Fukagawa M, Kido R, Komaba H etal. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis 2013; [Epub ahead of print] doi: 10.1053/j.ajkd.2013.08.011.
4. Wald R, Sarnak MJ, Tighiouart H etal. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008;52:531-540.
5. Kalantar-Zadeh K, Kuwae N, Regidor DL etal. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
6. Block GA, Klassen PS, Lazarus JM etal. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
7. Roman-Garcia P, Carrillo-Lopez N, Fernandez-Martin JL etal. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010;46:121-128.
8. Neves KR, Graciolli FG, dos Reis LM etal. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004;66:2237-2244.
9. Finch JL, Lee DH, Liapis H etal. Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification. Kidney Int 2013;84:1145-1153.
10. Cozzolino M, Staniforth ME, Liapis H etal. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003;64:1653-1661.
11. Ogata H, Koiwa F, Shishido K, Kinugasa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial 2005;9:11-15.
12. Koiwa F, Onoda N, Kato H etal. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-346.
13. Suzuki M, Kurihara R, Ozono E etal. Effects of PB-94 (Sevelamer Hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients-a randomized, open label, dose titration study of PB-94 versus Caltan® Tab. 500 (calcium carbonate). Kidney & Dial 2003; 55:383-400 (in Japanese).
14. Akizawa T, Kameoka C, Kaneko Y etal. Long-term treatment of hyperphosphatemia with bixalomer in japanese hemodialysis patients. Ther Apher Dial 2013;17:612-619.
15. Akizawa T, Origasa H, Kameoka C etal. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Ther Apher Dial 2014;18:122-131.
16. Hatakeyama S, Murasawa H, Narita T etal. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis. BMC Nephrol 2013;14:222.
17. Fukagawa M, Yokoyama K, Koiwa F etal. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013;17:247-288.
18. Dimenas E, Carlsson G, Glise H etal. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221:8-13.
19. Strid H, Simren M, Johansson AC etal. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephro Dial Trasplant 2002;17:1434-1439.
20. Dong R, Guo ZY. Gastrointestinal symptoms in patients undergoing peritoneal dialysis: multivariate analysis of correlated factors. World J Gastroenterol 2010;16:2812-2817.
21. Omori HSM, Koshikawa S, Kurihara R etal. Effects of PB-94 (Sevelamer Hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients -Longterm study of PB-94 -. Kidney Dial 2003; 55:513-531 (in Japanese).
22. Iwasaki Y, Takami H, Tani M etal. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients. Ther Apher Dial 2005;9:347-351.